Alnylam Pharmaceuticals, Inc. discovers, develops, and commercializes therapeutics based on ribonucleic acid interference. It offers ONPATTRO and AMVUTTRA for hereditary transthyretin-mediated amyloidosis; GIVLAARI for acute hepatic porphyria; OXLUMO for primary hyperoxaluria type 1; and Leqvio for hypercholesterolemia. It also develops vutrisiran, which is in phase III clinical trial for transthyretin amyloidosis (ATTR) with cardiomyopathy; Nucresiran that is in phase I clinical trial for ATTR amyloidosis; Fitusiran, which is in phase III clinical trial for hemophilia; cemdisiran that is in phase III clinical trial for Myasthenia Gravis and paroxysmal nocturnal hemoglobinuria, and geographic atrophy; and ALN-6400, which is in phase I clinical trial for bleeding disorders. In addition, the company is also developing Zilebesiran, which is in phase II clinical trial for hypertension; Rapirosiran that is in phase II clinical trial for Metabolic dysfunction-associated steatohepatitis; ALN-4324, which is in phase I clinical trial for type 2 diabetes mellitus; ALN-PNP that is in phase I clinical trial for non-alcoholic fatty liver disease; ALN-APOC3, which is in phase I clinical trial for dyslipidemia; Mivelsiran that is in phase II clinical trial for cerebral amyloid angiopathy, and phase I clinical trial for Alzheimer's disease; and ALN-HTT02 that is in phase I clinical trial for Huntington's disease. Further, it develops ALN-SOD, which is in phase II clinical trial for SOD1 Amyotrophic lateral sclerosis; Elebsiran that is in phase II clinical trial for Hepatitis B and D virus infections; ALN-BCAT that is in phase I clinical trial for hepatocellular carcinoma; and ALN-ANG3. It has collaborations with Regeneron Pharmaceuticals, Inc.; Roche Holding AG; Regeneron Pharmaceuticals, Inc.; Sanofi S.A.; Novartis AG; PeptiDream, Inc; Dicerna Pharmaceuticals, Inc.; and Ionis Pharmaceuticals, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.

Alnylam Pharmaceuticals Inc.

An announcement from Alnylam Pharma ( ($ALNY) ) is now available. On December 10, 2025, Alnylam Pharmaceuticals announced it had entered into priva...

Market Cap	$59.82B	P/E Ratio	216.06
52W High	$495.55	52W Low	$205.87
Div Yield	N/A	Payout Ratio	N/A
EPS Growth 3Y	32.9%	52W Position	66.2%
Overall Score	56	Value Score	40
Quality Score	76	Technical Score	54

EPS Current Est	$1.84	EPS Next Est	$7.4
EPS Growth Est	+302.2%	DPS Growth 3Y	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	ALNY	$397.55	-3.65%	1.65M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	ALNY	$397.55	-3.7%	1.65M
3
4
5
6

ALNY

ALNY

Key Metrics Overview

Growth Analysis

Revenue (5Y)

EBITDA (5Y)

Get Alnylam Pharmaceuticals Inc. Data in Excel

Get Alnylam Pharmaceuticals Inc. Data in Excel